Skip to content
MARKETS / NYSE / BFLY
NYSE · X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS · SMALL CAP

Butterfly Network, Inc. BFLY

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$97.6M
▲ 19.0% YoY
$-77.1M
$-16.0M
In brief

What this company does

The company markets and sells the Butterfly solution to healthcare systems, physicians and healthcare providers through a direct sales force, distributors and its eCommerce channel. The company's ultrasound devices fit in a healthcare professional's pocket and pair with cloud-connected software accessed through a mobile application. Butterfly iQ3 is currently FDA-cleared for sale in the United States and CE marked in Europe. The company generated total revenue of $97.6 million for the year ended December 31, 2025. Butterfly employed approximately 220 employees as of January 31, 2026, and sold its products in over 30 countries. The Company, formerly known as Longview Acquisition Corp., was incorporated in Delaware in 2020 as a blank check company. Butterfly Network, Inc., previously Legacy Butterfly, was founded in 2011 and completed a business combination with Longview on February 12, 2021, after which Longview was renamed Butterfly Network, Inc.

Written from the business description in Butterfly Network, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth
USD 97.6M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 97.6 · Net income -77.1
40M80M-80M-160M2019202020212022202320242025
Compound annual growth
+10.0%
+16.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−79 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -88.5% · Net -79.0%
-100%-200%-300%2019202020212022202320242025
ROE
FY2025 · ROE -42.2%
-20%-40%-60%2019202020212022202320242025

Each USD of equity lost 42 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -16.0
-80M-160M2019202020212022202320242025

Total assetsUSD 296.5M
EquityUSD 196.0M
CashUSD 150.5M
Current ratio3.83×

Equity funds 66% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.10.10.10.10.10.00.0
Operating income $B−0.1−0.1−0.1−0.2−0.2−0.2−0.1
EBITDA $B−0.1−0.1−0.1−0.2−0.2−0.2−0.1
Income tax $B0.0−0.00.00.00.00.0·
Net income $B−0.1−0.1−0.1−0.2−0.0−0.2−0.1
Free cash flow $B−0.0−0.0−0.1−0.2−0.2−0.1−0.1
EPS, diluted $−0.31−0.34−0.65−0.84−0.19−26.87−17.08
Dividend / sh $0.000.000.000.000.00··
Payout %·······
ROE %−42.2−37.3−49.0−43.7−75.6··
Shares out B·······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityX-Ray Apparatus & Tubes & Related Irradiation Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018

Share this section

Download image